Discovery of F-18 labeled repurposed CNS drugs by computational strategy for effective tau imaging and alzheimer’s diagnosis
PLOS One · 2025
DOI: 10.1371/journal.pone.0338901 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Pan Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde), Changde, Ch…. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Drug Repositioning, Fluorine Radioisotopes. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Changde Science and Technology Bureau.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) remains a significant challenge in diagnosis and treatment, with current methods insufficient for early detection. A major obstacle is the lack of effective imaging agents targeting the Tau protein, which plays a key role in AD pathology. To address this, we developed a computational methodology for selecting F-18 labeled drug candidates from a library of CNS-penetrant compounds curated from literature and databases. The library, consisting of 977 compounds, was evaluated based on clinical data, target proteins, pathways, toxicity, and other relevant factors. We implemented Python-based algorithms to select the top 39 compounds from virtual screening results, prioritizing those with optimal Tau binding affinity and BBB permeability. Additionally, we developed an algorithm to identify F-18 labeling candidates that maintain their biological activity post-labeling. We then performed virtual screening of an F-18 labeled drug library and selected the top 3 compounds based on stability and imaging potential. The selected compounds exhibited molecular weights of 350–520 Da, favorable logP values (2.05–2.72), and high BBB permeability. Our findings indicate that Drug 388 (BI-D1870), binds to Tau with a binding free energy of ΔG = −8.79 kcal/mol. Drug 416 (reported BRAF inhibitor, RG6344) shows a binding free energy of ΔG = −7.91 kcal/mol, while Drug 610 (Iloperidone/HP 873), a D2/5-HT2 receptor antagonist, exhibits a predicted binding free energy of ΔG = −6.88 kcal/mol with the target Tau protein respectively. Molecular dynamics simulations confirmed stable Tau-drugs interactions, with minimal RMSD fluctuations, indicating strong binding. The F-18 label enabled real-time PET imaging, allowing non-invasive tracking of the drug’s binding to Tau in the brain. Our approach provides a comprehensive solution to the current limitations in Alzheimer’s diagnosis by offering F-18 labeled drugs that effectively target Tau protein without compromising their biological activity, advancing both diagnostic and therapeutic strategies for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde), Changde, China.
- Department of Nuclear Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde), Changde, China.
- Department of Paediatrics, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde), Changde, China.
- Centre for Reproductive Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde), Changde, China.
- School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing, China.
ORCID-Profile: Chong Cheng
Förderung
- Changde Science and Technology Bureau
Zitieren
APA
Tang, P., Chen, X., Li, P., Zhang, L., Tang, B., Wen, J., Liu, Y., Kalsoom, I., & Cheng, C. (2025). Discovery of F-18 labeled repurposed CNS drugs by computational strategy for effective tau imaging and alzheimer’s diagnosis. PLOS One. https://doi.org/10.1371/journal.pone.0338901
Vancouver
Tang P, Chen X, Li P, Zhang L, Tang B, Wen J, et al. Discovery of F-18 labeled repurposed CNS drugs by computational strategy for effective tau imaging and alzheimer’s diagnosis. PLOS One. 2025. doi:10.1371/journal.pone.0338901
BibTeX
@article{Tang2025,
author = {Tang, Pan and Chen, Xuehua and Li, Pingping and Zhang, Ling and Tang, Bin and Wen, Jun and Liu, Yan and Kalsoom, Iqra and Cheng, Chong},
title = {Discovery of F-18 labeled repurposed CNS drugs by computational strategy for effective tau imaging and alzheimer’s diagnosis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0338901}
}
EUVIMED